Casdin Capital’s Sana Biotechnology SANA Stock Holding History

Casdin Capital’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-750,000	Closed	-$2.9M	–	41
2023 Q3	$2.9M	Hold	750,000	–	–	0.32%	33
2023 Q2	$4.47M	Buy	+750,000	New	+$4.32M	0.39%	30
2022 Q1	–	Sell	-60,000	Closed	-$929K	–	52
2021 Q4	$929K	Hold	60,000	–	–	0.03%	53
2021 Q3	$1.35M	Hold	60,000	–	–	0.03%	54
2021 Q2	$1.18M	Hold	60,000	–	–	0.03%	54
2021 Q1	$2.01M	Buy	+60,000	New	+$1.95M	0.06%	47

Other funds holding SANA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Casdin Capital's SANA Position: Q4 2023 in Review

Casdin Capital sold out of Sana Biotechnology (SANA) in Q4 2023, closing a stake of 750,000 shares — an estimated $2.9M sold.

Casdin Capital first reported a position in SANA in Q1 2021 and held it in 6 quarters. The position peaked at $4.47M in Q2 2023. 132 funds tracked by Wall St. Rank hold SANA as of Q4 2023.

Casdin Capital reported no remaining Sana Biotechnology position as of Q4 2023 after selling out during the quarter.
Casdin Capital sold 750,000 Sana Biotechnology shares in Q4 2023, an estimated $2.9M.
Casdin Capital first reported a position in Sana Biotechnology in Q1 2021 and held it in 6 quarters.
Casdin Capital's Sana Biotechnology position peaked at $4.47M in Q2 2023.
132 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2023.

Based on Casdin Capital's 13F filing for Q4 2023, filed 14 Feb 2024.